Libevitug for Hepatitis D
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Are You a Good Fit for This Trial?
This trial is for adults with chronic hepatitis D infection for at least 6 months, who have a certain level of the virus in their blood and mildly to moderately elevated liver enzymes. Participants must be able to follow study instructions and give consent.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Libevitug
Trial Overview
The study is testing two different doses of a drug called libevitug (10 mg/kg or 20 mg/kg) compared to delayed treatment. Participants are randomly assigned to groups, and everyone knows which treatment they receive.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Participants will receive libevitug at a dose of 20 mg/kg Q2W via intravenous infusion for 96 weeks
Participants will receive libevitug at a dose of 10 mg/kg Q2W via intravenous infusion for 96 weeks
Participants will be observed as comparator for 48 weeks, then to receive libevitug 20 mg/kg for 48 weeks
Find a Clinic Near You
Who Is Running the Clinical Trial?
Huahui Health
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.